CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Exploring CAR T-Cell Therapy During the COVID-19 Pandemic: Mitigation and Management of Adverse Events

April 16th 2020

This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor T cells. Join us Tuesday, May 26, 2020 at 8 PM EST.

CAR T-Cell Therapy During the COVID-19 Pandemic: A Closer Look at Real-World Data

April 16th 2020

CAR T-Cell Therapy During the COVID-19 Pandemic: A Closer Look at Real-World Data

April 16th 2020

Dr. Park on Ongoing Research Efforts With CAR T-Cell Therapies in ALL

April 2nd 2020

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of CAR T-cell therapies in patients with acute lymphocytic leukemia.

Dr. Awan on Novel Strategies Under Exploration in Relapsed/Refractory CLL

April 2nd 2020

Farrukh Awan, MD, discusses novel approaches under investigation in relapsed/refractory chronic lymphocytic leukemia.

Dr. Levine on Programmed Anticancer Immunity With T-cell and NK-cell Therapies

March 31st 2020

Bruce L. Levine, PhD, discusses engineered anticancer immunity with T-cell and natural killer–cell therapies.

Dr. Berdeja on Updated Data With bb21217 in Multiple Myeloma

March 31st 2020

Jesus Berdeja, MD, the director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses updated data with bb21217 in multiple myeloma.

Outpatient CAR T-Cell Therapy Found Safe, Effective in Large B-Cell Lymphoma

March 30th 2020

Carlos R. Bachier, MD, discusses the use of CAR T-cell therapy in the outpatient setting. He also shared insight on the evolving paradigm of graft-versus-host disease.

Optimal Management Needed for Blood Count Recovery Following CAR T-Cell Therapy

March 27th 2020

Tania Jain, MBBS, discusses blood count recovery in patients with hematology malignancies who receive CAR T-cell therapy.

Community Oncologist Discusses CAR T-Cell Therapy and Other Hematology Advances

March 27th 2020

Sameer Desai, MD, discusses his experience in the hematology field and how CAR T-cell therapy has evolved and its potential integration into community centers.

Expert Highlights Contributing Elements to Hemopoietic Recovery From CAR T-Cell Therapy

March 26th 2020

Craig Sauter, MD, discusses results of a retrospective, real-world review of patients with hematologic malignancies who developed cytopenia post-CAR T-cell therapy.

Key AE Management Strategies in Place for CAR T-Cell Therapy in Hematologic Cancers

February 29th 2020

With the main toxicities associated with CAR T-cell therapy being cytokine release syndrome and neurotoxicity, a multidisciplinary approach is vital to providing inclusive care to patients receiving this type of treatment.

Dr. Tzachanis on Data With Lisocabtagene Maraleucel in Lymphoma

February 28th 2020

Dimitrios Tzachanis, MD, PhD, discusses data with lisocabtagene maraleucel (liso-cel) in large B-cell lymphoma, as well as the differences between axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah).

Dr. Adusumilli on the Development of CAR T Cells in Solid Tumors

February 28th 2020

Prasad S. Adusumilli, MD, FACS, discusses the current role of chimeric antigen receptor T-cell therapy as treatment of patients with solid tumors and how this is evolving compared to CAR T cells in hematologic malignancies.

Adding CAR T-Cell Therapy to the Electronic Medical Record

February 28th 2020

Andrea Price, APN, discusses adding CAR T-cell therapy to the electronic medical record.

Axi-Cel Toxicity in LBCL May Be Alleviated With Earlier Steroid Use

February 22nd 2020

Early steroid intervention has the potential to reduce the severity of adverse events associated with axicabtagene ciloleucel in patients with refractory large B-cell lymphoma, according to an analysis of the phase I/II ZUMA-1 trial.

Dr. Jain on Hematopoietic Recovery Following CAR T-Cell Therapy

February 20th 2020

Tania Jain, MBBS, discusses hematopoietic recovering following treatment with a chimeric antigen receptor T-cell therapy in patients with hematologic malignancies.

Dr. Abramson on the TRANSCEND NHL 001 Trial in Large B-Cell Lymphoma

February 15th 2020

Jeremy S. Abramson, MD, discusses the results of the multicenter phase I TRANSCEND NHL 001 study evaluating the safety and efficacy of lisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma.

FDA Grants Priority Review to Liso-Cel in Large B-Cell Lymphoma

February 13th 2020

The FDA has granted a priority review designation to a biologics license application for the anti-CD19 CAR T-cell therapy lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma after at least 2 prior therapies.

Dr. Kansagra on Remaining Questions With CAR T-Cell Therapy in Multiple Myeloma

February 13th 2020

Ankit Kansagra, MD, discusses remaining questions with CAR T-cell therapy in multiple myeloma.